Exact Mass: 471.1634

Exact Mass Matches: 471.1634

Found 51 metabolites which its exact mass value is equals to given mass value 471.1634, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

CAY10650

CAY10650

C28H25NO6 (471.1682)


CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion[1][2].

   

Asp His Asn Ser

(3S)-3-amino-3-{[(1S)-1-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}ethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asp His Ser Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C17H25N7O9 (471.1714)


   

Asp Asn His Ser

(3S)-3-amino-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asp Asn Ser His

(3S)-3-amino-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-hydroxyethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asp Ser His Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C17H25N7O9 (471.1714)


   

Asp Ser Asn His

(3S)-3-amino-3-{[(1S)-1-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}-2-hydroxyethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

His Asp Asn Ser

(3S)-3-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

His Asp Ser Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carboxypropanamido]-3-hydroxypropanamido]-3-carbamoylpropanoic acid

C17H25N7O9 (471.1714)


   

His Asn Asp Ser

(3S)-3-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

His Asn Ser Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]-3-hydroxypropanamido]butanedioic acid

C17H25N7O9 (471.1714)


   

His Ser Asp Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-carboxypropanamido]-3-carbamoylpropanoic acid

C17H25N7O9 (471.1714)


   

His Ser Asn Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-carbamoylpropanamido]butanedioic acid

C17H25N7O9 (471.1714)


   

Asn Asp His Ser

(3S)-3-[(2S)-2-amino-3-carbamoylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asn Asp Ser His

(3S)-3-[(2S)-2-amino-3-carbamoylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-hydroxyethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asn His Asp Ser

(3S)-3-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-1-carboxy-2-hydroxyethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asn His Ser Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]butanedioic acid

C17H25N7O9 (471.1714)


   

Asn Ser Asp His

(3S)-3-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Asn Ser His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C17H25N7O9 (471.1714)


   

Ser Asp His Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carboxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanoic acid

C17H25N7O9 (471.1714)


   

Ser Asp Asn His

(3S)-3-[(2S)-2-amino-3-hydroxypropanamido]-3-{[(1S)-2-carbamoyl-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Ser His Asp Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carboxypropanamido]-3-carbamoylpropanoic acid

C17H25N7O9 (471.1714)


   

Ser His Asn Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carbamoylpropanamido]butanedioic acid

C17H25N7O9 (471.1714)


   

Ser Asn Asp His

(3S)-3-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C17H25N7O9 (471.1714)


   

Ser Asn His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C17H25N7O9 (471.1714)


   

Dorsomorphin 2HCl

Dorsomorphin 2HCl

C24H27Cl2N5O (471.1593)


Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).

   

Quinacrine dihydrochloride

Quinacrine (dihydrochloride)

C23H32Cl3N3O (471.1611)


D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics D000970 - Antineoplastic Agents D004791 - Enzyme Inhibitors

   
   

NeuAcalpha2-3Galbeta

NeuAcalpha2-3Galbeta

C17H29NO14 (471.1588)


   

N-[1-[4-(2-methoxyphenyl)-1-piperazinyl]-1-thiophen-2-ylpropan-2-yl]benzenesulfonamide

N-[1-[4-(2-methoxyphenyl)-1-piperazinyl]-1-thiophen-2-ylpropan-2-yl]benzenesulfonamide

C24H29N3O3S2 (471.165)


   

4-(2-Hydroxybenzylamino)-N-(3-(4-fluorophenoxy)phenyl)piperidine-1-sulfonamide

4-(2-Hydroxybenzylamino)-N-(3-(4-fluorophenoxy)phenyl)piperidine-1-sulfonamide

C24H26FN3O4S (471.1628)


   

2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-YL)ethyl]-4-(4-ethoxy-1,1-biphenyl-4-YL)-4-oxobutanoic acid

2-[2-(1,3-Dioxo-1,3-dihydro-2H-isoindol-2-YL)ethyl]-4-(4-ethoxy-1,1-biphenyl-4-YL)-4-oxobutanoic acid

C28H25NO6 (471.1682)


   

alpha-Neup5Ac-(2->6)-beta-D-Galp

alpha-Neup5Ac-(2->6)-beta-D-Galp

C17H29NO14 (471.1588)


alpha-Neup5Ac-(2->6)-D-Galp in which the anomeric configuration of the reducing-end D-galactose residue is beta.

   

alpha-Neu5Ac-(2->3)-D-Gal

alpha-Neu5Ac-(2->3)-D-Gal

C17H29NO14 (471.1588)


An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position

   

1-[(4-fluorophenyl)methyl]-4-(3,4,5-trimethoxyphenyl)-4H-pyridine-3,5-dicarboxylic acid dimethyl ester

1-[(4-fluorophenyl)methyl]-4-(3,4,5-trimethoxyphenyl)-4H-pyridine-3,5-dicarboxylic acid dimethyl ester

C25H26FNO7 (471.1693)


   

alpha-Neup5Ac-(2->6)-D-Galp

alpha-Neup5Ac-(2->6)-D-Galp

C17H29NO14 (471.1588)


An amino disaccharide consisting of D-galactose having an alpha-N-acetylneuraminyl residue attached at the 6-position

   

3-[2,4-dioxo-1-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-quinazolinyl]-N-(2-furanylmethyl)propanamide

3-[2,4-dioxo-1-[(4-oxo-2-pyrido[1,2-a]pyrimidinyl)methyl]-3-quinazolinyl]-N-(2-furanylmethyl)propanamide

C25H21N5O5 (471.1543)


   

3-O-{5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl}-alpha-D-galactopyranose

3-O-{5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranonosyl}-alpha-D-galactopyranose

C17H29NO14 (471.1588)


   

3-O-(5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranonosyl)-D-galactopyranose

3-O-(5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranonosyl)-D-galactopyranose

C17H29NO14 (471.1588)


   
   
   
   

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranose

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-beta-D-galacto-hexopyranose

C17H29NO14 (471.1588)


   

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-alpha-D-galacto-hexopyranose

5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosylonic acid-(2->3)-alpha-D-galacto-hexopyranose

C17H29NO14 (471.1588)


   

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1,3-dihydroxy-2-methyl-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-[(1,3-dihydroxy-2-methyl-1-phenylpropan-2-yl)sulfanyl]ethyl}-C-hydroxycarbonimidoyl)butanoic acid

C20H29N3O8S (471.1675)


   

(2R,4S,5R,6R)-5-acetamido-2-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

(2R,4S,5R,6R)-5-acetamido-2-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid

C17H29NO14 (471.1588)


   

alpha-Neup5Ac-(2->3)-beta-D-Galp

alpha-Neup5Ac-(2->3)-beta-D-Galp

C17H29NO14 (471.1588)


An amino disaccharide consisting of beta-D-galactose having an alpha-N-acetylneuraminyl residue attached at the 3-position

   

alpha-Neup5Ac-(2->3)-alpha-D-GalpNAc

alpha-Neup5Ac-(2->3)-alpha-D-GalpNAc

C17H29NO14 (471.1588)


An amino disaccharide comprised of an N-acetyl-alpha-neuraminyl residue linked (2->3) to N-acetyl-alpha-D-galactosamine

   
   

n-{[(2r,3s,4r,5s)-5-(2,4-dihydroxypyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-2-{[1-hydroxy-2-(c-hydroxycarbonimidoylamino)ethylidene]amino}pentanediimidic acid

n-{[(2r,3s,4r,5s)-5-(2,4-dihydroxypyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-2-{[1-hydroxy-2-(c-hydroxycarbonimidoylamino)ethylidene]amino}pentanediimidic acid

C17H25N7O9 (471.1714)